TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.

Chung-Han Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.